Table Of Content
They don't really have abnormalities of very long-chain fatty acids, but we did see some reductions in very long-chain fatty acids in that prior Phase one experience. So if we can see somewhere in the mid to high 10s on the very long-chain fatty acid reduction that would be a pretty interesting, hopefully more than that. But that would be probably that the gating factor to consider further development in X-linked adrenoleukodystrophy.
Design Therapeutics Earnings History by Quarter
On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. With respect to what would be available and when will that those are the primary components of the data that we'll receive. We will be receiving probably little later data on paired biopsy reads, you know, what is someone's NASH, better, unchanged or worse at the end of the treatment period that that kind of thing since those take a little bit longer to evaluate. So we'll we haven't received the final data from the study.
DSGN Related ETFs
Neoleukin, old ending: De novo protein player lays off 70% of staff, searches for strategic alternative - Fierce Biotech
Neoleukin, old ending: De novo protein player lays off 70% of staff, searches for strategic alternative.
Posted: Thu, 09 Mar 2023 08:00:00 GMT [source]
A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Design Therapeutics' stock was trading at $2.65 on January 1st, 2024.
Design Therapeutics Company Profile
It showed in the somewhere in the 10s range for a NASH resolution and it did show some improvement in fibrosis. So to the extent we have a similar or better liver fat reduction, I think that would be sort of the range we would be looking at for NASH resolution and fibrosis improvement. And with respect to the overall market, yes, it does seem like there is a rapid expansion of the GLP-1 utilization. And so that probably does create some some some headwind on the uptake of new NASH drugs, but we've not had an approved drug for NASH. I think it's going to be really important to see how the first few quarters and mature there.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Gain deeper insights into company revenues with a detailed analysis of revenue sources. Explore the updated Options feature, providing in-depth data, and a 3D viewing option.
And you know, I think a couple of things we're right now in this very acute stage where these compounds have just been recently approved for weight loss and there is just overwhelming demand and the supply isn't quite there. We don't consider that to be a terminal state. We do see from the existing companies in the space, it ramp up in manufacturing capacity. We know on the contractor side, there is a massive attention being paid paid to this this issue. And so I think the supply dynamics will probably evolve over the next few years, still going to be a difficult challenge, but I think we're not in a permanent shortage state, we don't think. So with the translatability for liver fat to histologic improvement.
The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. We are a biopharmaceutical company advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet need.
Financial Strength
And maybe there is a backlog of people waiting to trial and a backlog of clinicians waiting to do I prescribe It's so unknown right now, it's hard to hard to project, but it is true that the GLP ones are getting more and more utilization. And there's a middle question in there, I think I skipped. Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO, and Greg Zante, Viking's CFO.
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
And do you think you'll have enough data to support less frequent dosing? And then what are your latest thoughts on a Phase IIb study? And then I had a follow-up question, if I could. Two eight zero nine, what's the general translatability of kind of the 12 week MRI PDFF result into later histology endpoints and on are you planning to move the program into mass program into Phase three yourself? And then maybe as a third and final question, how do you think that thyroid beta agonist market will develop. There's kind of been some recent evidence that GLP ones, both dual GLP-1 and GIP.
Jump Financial LLC now owns 46,700 shares of the company's stock worth $110,000 after acquiring an additional 34,561 shares during the last quarter. 56.64% of the stock is owned by hedge funds and other institutional investors. 7 analysts have issued 1-year target prices for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00.
And I'll now turn the call over to Brian Lian for his initial comments. Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira was co-founded by Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design at the University of Washington School of Medicine. The company now employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr. Baker’s lab. Xaira’s broader team will advance these models and develop new methods that can connect the world of biological targets and engineered molecules to the human experience of disease. And I think we'll have to see what the data look like, but we'll be probably looking for a partner with the program, but hard to say without having a look at the data first.
Design Therapeutics, Inc. has a 12 month low of $1.94 and a 12 month high of $8.47. The firm's fifty day simple moving average is $3.25 and its 200-day simple moving average is $2.66. Design Therapeutics has a widening net earnings loss and a declining liquidity position. Also, there’s no guarantee that the FDA will fully approve the company’s clinical programs. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud.
In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10 Q filing with the Securities and Exchange Commission, which we expect to file later today. I'll now go over our results for the first quarter ended March 31st, 2024. Research and development expenses were $24.1 million for the three months ended March 31st, 2024, compared to $11 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for our drug candidates, preclinical studies, clinical studies, stock-based compensation, salaries and benefits and services provided by third-party consultants. General and administrative expenses were $10 million for the three months ended March 31st, 2024, compared to $9.5 million for the same period in 2023. The increase was primarily due to increased expenses related to stock-based compensation, salaries and benefits and services provided by third-party consultants, partially offset by decreased expenses related to legal and patent services.
After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Even if one or more of Design Therapeutics’ treatments is fully accepted by regulators, this doesn’t necessarily mean the company will succeed on a financial level. Design Therapeutics has been unprofitable, quarter after quarter.
These issues can, to a large extent, be attributed to Design Therapeutics’ spending. The company’s operating expenses grew dramatically from 2021 to 2022. Moreover, there’s no mention of cost reduction in Design Therapeutics’ most recently published earnings press release.
Finally, during the quarter, Viking completed a public offering of common stock raising gross proceeds of approximately $630 million. These funds substantially strengthen the Company's balance sheet and will support our plans to aggressively develop our pipeline. I'll provide further details on our operations and development activities after we review our financial results for the first quarter of 2024. For that, I'll turn the call over to Greg Zante, Viking's Chief Financial Officer.
No comments:
Post a Comment